Hester Biosciences Limited has successfully concluded its postal ballot process for the re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director, with shareholders demonstrating overwhelming support for the leadership continuity. The company announced the results on 10 March 2026, following a comprehensive remote e-voting process that adhered to regulatory requirements and submitted formal proceedings to stock exchanges.

Postal Ballot Results

The special resolution for Mr. Gandhi's re-appointment received exceptional shareholder approval, with the voting results clearly indicating strong confidence in the company's leadership direction.

Re-appointment Details

The approved resolution grants Mr. Rajiv Gandhi (DIN: 00438037) a three-year term as CEO & Managing Director, effective from 1 April 2026 to 31 March 2029. The resolution also authorizes the Board of Directors to vary, alter, and modify the terms and conditions of his remuneration structure within prescribed limits.

Regulatory Compliance and Documentation

The company submitted comprehensive documentation to BSE Limited (Scrip Code: 524669) and National Stock Exchange of India Limited (Symbol: HESTERBIO) on 10 March 2026, including proceedings of the postal ballot process, voting results, and scrutinizer's report in accordance with Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Category-wise Voting Pattern

The voting results showed strong support across different shareholder categories with detailed breakdowns provided in the regulatory filings:

Scrutinizer's Report and Process Validation

Mr. Tapan Shah (FCS: 4476), Practicing Company Secretary, served as the appointed scrutinizer to ensure fair and transparent proceedings. The scrutinizer's report confirmed that the postal ballot process was conducted in strict compliance with Sections 196, 197, 198, and 203 of the Companies Act, 2013, and all applicable regulatory requirements.

The postal ballot notice was sent electronically to all 12,810 equity shareholders as on the cut-off date, utilizing Central Depository Services (India) Limited as the e-voting service provider platform. The resolution has been duly passed with the requisite majority, and the Board of Directors is now authorized to implement the re-appointment and handle all necessary formalities.

Hester biosciences Limited has announced that the audio recording of its earnings conference call for Q3 FY26 results is now available on the company's official website. The teleconference was conducted on 30 January 2026 to discuss the financial performance for the quarter and nine months period ended 31 December 2025.

Regulatory Compliance and Disclosure

The company has made this announcement in compliance with Regulations 30 and 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to ensure transparency and timely disclosure of material information to stakeholders.

Access Details

The earnings call recording has been made accessible to all shareholders and investors through the company's dedicated investor relations section. The audio recording can be accessed through the company's website at the earnings call section.

Corporate Communication

The formal communication was signed by Vinod Mali, Company Secretary & Compliance Officer, and submitted to both major stock exchanges where Hester Biosciences shares are listed. The notification was sent to BSE Limited and National Stock Exchange of India Limited on 30 January 2026.

Stakeholder Engagement

By making the earnings call recording available online, Hester Biosciences ensures that stakeholders who could not participate in the live teleconference can access the management's commentary on quarterly performance. This approach enhances transparency and provides equal access to material information for all investors and shareholders.